Financing What Actually Works

A discussion of why the pharmacologic treatment of fibromyalgia underperforms, why drug price is not the binding constraint, and how covered entities can nonetheless use 340B program margin to finance the care model the evidence supports.
Rapha Insights

Evidence-aware perspectives on fibromyalgia, complex chronic care and the information that develops over time.

Female doc discharging FM patient.

About Rapha Insights

We distinguish published evidence, emerging hypotheses and lived experience. Educational content is designed to support informed discussion—not replace diagnosis or individualized clinical care.


Facebook
LinkedIn
Email

Better understanding begins with better conversations

Be among the first to hear about new Rapha resources, programs, research opportunities, and ways to participate.